With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.
Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics Through Clinical Proof of Concept
Autoimmune Diseases, Biology, Biotech, Business, Drug Discovery, Fibrosis, Financing, Human Cells, Immuno-oncology, Integrins, Preclinical Data, Series B Preferred StockMorphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.
Alnylam and Sanofi announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for rare genetic diseases.
